IBN expands citrus portfolio with Sytrinol acquisition

26 Jul 2021 --- Ingredients by Nature (IBN) has acquired the Sytrinol brand, which uses compounds in citrus peel and palm fruit extracts to support heart health. IBN will now explore the synergistic combination of its clinically backed lemon flavonoid brand Eriomin with Sytrinol.

The deal includes marketing assets associated with the brand, such as logos, web domains, human clinical trials, patents and marketing data. Financial details have not been disclosed.

“We look forward to discovering additional ways to innovate with Sytrinol to bring it to an expanded consumer base,” says Rob Brewster, president of IBN.

Building out citrus
IBN emphasizes that Sytrinol will be a good fit into its existing portfolio of citrus ingredients. Prior to the acquisition, IBN manufactured the formula for many years. This includes years of experience manufacturing citrus-derived polymethoxylated flavones (PMFs), a key ingredient in Sytrinol. 

Sytrinol influences healthy cholesterol levels, healthy LDL levels with improved LDL:HDL ratio and healthy triglyceride levels.

Research has shown that its positive effects are measurable in as little as four weeks. The randomized, double-blind, placebo-controlled research showed a 27 percent reduction in cholesterol levels, 25 percent reduction in LDL cholesterol levels and 31 percent reduction in triglyceride levels. 

According to IBN, the extent to which the ingredient functions has rarely been seen with other heart health ingredients.Sytrinol and Eriomin could be combined for prediabetes management and cardiovascular support.

Tackling key concerns
Excessive blood glucose has been linked to unhealthy cholesterol and triglyceride levels, notes IBN. Eriomin already delivers a tri-pronged approach to prediabetes management by helping to address insulin resistance, pro-inflammatory cytokine production and oxidative stress.

Adding in Sytrinol’s heart health benefits could create a combination with even greater potential for prediabetes management and cardiovascular support.  

Other companies have also been addressing the diabetes space, with Euromed’s ABAlife fig extract recently being found to increase muscle metabolism and promote insulin sensitivity.

In April, Pendulum raised US$54 million in its series C funding round for its products targeting the microbiome, including a symbiotic that controls blood glucose levels. 

Meanwhile, IBN continues to grow its range of extracts and other ingredients. Last year, it gained patent approval for the use of eriocitrin in its ingredient formulations, including Eriomin. The company also offers an e-sports version of the ingredient. 

Edited by Katherine Durrell